Comments
Loading...

ImmunityBio

IBRXNASDAQ
Logo brought to you by Benzinga Data
$4.95
-0.5-9.17%
At close: -
$4.98
0.030.61%
After Hours: 7:59 PM EDT
Q3 2024 Earnings were released on Tue Nov 12th, before the market open
Consensus Rating1
Buy
Highest Price Target1
$30.00
Lowest Price Target1
$4.75
Consensus Price Target1
$18.19

ImmunityBio (NASDAQ:IBRX) Stock, Analyst Ratings, Price Targets, Forecasts

ImmunityBio Inc has a consensus price target of $18.19 based on the ratings of 4 analysts. The high is $30 issued by D. Boral Capital on November 12, 2024. The low is $4.75 issued by Piper Sandler on August 19, 2024. The 3 most-recent analyst ratings were released by D. Boral Capital, EF Hutton, and Piper Sandler on November 12, 2024, October 23, 2024, and August 19, 2024, respectively. With an average price target of $21.58 between D. Boral Capital, EF Hutton, and Piper Sandler, there's an implied 333.40% upside for ImmunityBio Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Aug
0
0
0
0
Oct
0
0
0
0
Nov
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

D. Boral Capital
EF Hutton
Piper Sandler
Jefferies

1calculated from analyst ratings

Analyst Ratings for ImmunityBio

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for ImmunityBio (IBRX) stock?

A

The latest price target for ImmunityBio (NASDAQ:IBRX) was reported by D. Boral Capital on November 12, 2024. The analyst firm set a price target for $30.00 expecting IBRX to rise to within 12 months (a possible 502.41% upside). 5 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ImmunityBio (IBRX)?

A

The latest analyst rating for ImmunityBio (NASDAQ:IBRX) was provided by D. Boral Capital, and ImmunityBio maintained their buy rating.

Q

When was the last upgrade for ImmunityBio (IBRX)?

A

There is no last upgrade for ImmunityBio

Q

When was the last downgrade for ImmunityBio (IBRX)?

A

The last downgrade for ImmunityBio Inc happened on May 12, 2023 when Piper Sandler changed their price target from $10 to $4 for ImmunityBio Inc.

Q

When is the next analyst rating going to be posted or updated for ImmunityBio (IBRX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ImmunityBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ImmunityBio was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.

Q

Is the Analyst Rating ImmunityBio (IBRX) correct?

A

While ratings are subjective and will change, the latest ImmunityBio (IBRX) rating was a maintained with a price target of $30.00 to $30.00. The current price ImmunityBio (IBRX) is trading at is $4.98, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch